

## Gremubamab

Cat. No.:	HY-P99649
CAS No.:	1800381-36-5
Target:	Bacterial
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections [1][2].	
<b>In Vivo</b>	Gremubamab (1, 5, 15 mg/kg; i.v.; at 1 h postinfection) improves survival outcomes in rabbit acute pneumonia model <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Rabbits (acute pneumonia model) <sup>[2]</sup>
	Dosage:	1, 5, 15 mg/kg
	Administration:	I.v.; at 1 h postinfection
	Result:	Improved survival outcomes in a dose-dependent manner in a rabbit acute pneumonia model.

### REFERENCES

[1]. Chastre J, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26(1):355.

[2]. Le HN, et al. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA